Niagen confirms operations remain resilient amid new tariff developments

Niagen Bioscience (NAGE) reaffirms that the manufacturing of its Niagen ingredient and Tru Niagen and pharmaceutical-grade Niagen(R) products remain resilient amid the recently enacted global tariffs. “We made the decision to build a U.S.-based supply chain for Niagen to safeguard long-term resilience, trust, and quality,” said Rob Fried, CEO of Niagen Bioscience. “That foresight is proving valuable now. We remain confident in our ability to deliver Niagen products to customers and long-term stability to shareholders.”